share_log

盈康生命获华安证券买入评级，经营质量持续提升，期待定增落地后的新发展

JRJ Finance ·  Aug 23 15:37  · Ratings

8月23日，盈康生命获华安证券买入评级，近一个月盈康生命获得2份研报关注。

研报预计2024~2026年将实现营业收入17.65/20.48/24.29亿元，同比+20.0%/16.0%/18.6%；实现归母净利润126/154/197百万元，同比+25.2%/22.1%/28.5%。研报认为，我们看好公司医疗服务&器械双板块驱动战略，器械板块内生+外延有望实现高增长；医疗服务板块有望保持稳健增长。

风险提示：政策不确定性风险，器械板块并购不及预期风险，医院扩张不及预期风险。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment